Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Cost of Revenue: 2020-2023

Historic Cost of Revenue for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to $13.7 million.

  • ADC Therapeutics' Cost of Revenue rose 960.23% to $13.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $28.8 million, marking a year-over-year increase of 603.45%. This contributed to the annual value of $4,579 for FY2022, which is 228.72% up from last year.
  • ADC Therapeutics' Cost of Revenue amounted to $13.7 million in Q3 2023, which was down 5.02% from $14.5 million recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Cost of Revenue peaked at $14.5 million during Q2 2023, and registered a low of $489 during Q4 2022.
  • Moreover, its 3-year median value for Cost of Revenue was $559,500 (2022), whereas its average is $3.3 million.
  • Examining YoY changes over the last 5 years, ADC Therapeutics' Cost of Revenue showed a top increase of 1,772.73% in 2022 and a maximum decrease of 36.49% in 2022.
  • Over the past 4 years, ADC Therapeutics' Cost of Revenue (Quarterly) stood at $2.6 million in 2020, then reached $770 in 2021, then plummeted by 36.49% to $489 in 2022, then skyrocketed by 960.23% to $13.7 million in 2023.
  • Its Cost of Revenue stands at $13.7 million for Q3 2023, versus $14.5 million for Q2 2023 and $590,000 for Q1 2023.